CASGEVY expands, but profit remains a distant target
- CASGEVY is approved in multiple countries and the FDA recently expanded the label to patients ages 2 and older in the US.
- CRISPR gets 40 percent of CASGEVY net profits or losses, while Vertex controls key manufacturing and launch work.
- Q2 2026 collaboration expense fell to $40.3 million from $45.2 million a year earlier as CASGEVY revenue helped offset costs.
- The company had roughly $2.4 billion in cash and equivalents in early 2026 following a convertible note raise.
- The bear case is still real as management expects commercial expenses to exceed revenue in the near term.
A real launch, not yet a profit story
CRISPR Therapeutics has crossed an important line. CASGEVY is no longer just a science project. It is an approved CRISPR-based medicine sold with Vertex for severe sickle cell disease and transfusion-dependent beta-thalassemia. In July 2026, the FDA expanded that approval to patients as young as 2 years old. That validates the company’s editing platform in a way few biotech peers can claim.
The latest updates continue to weaken the bear case. Q2 2026 collaboration expense fell to $40.3 million from $45.2 million in Q2 2025 because CRISPR’s share of CASGEVY revenue rose. That metric shows the launch is gradually moving toward profit for CRISPR, neutralizing some of the heavy launch costs.
The hard part is that CASGEVY still burns cash for CRISPR today. The company no longer has the option to defer its share of CASGEVY costs, and management has said those expenses are expected to exceed its share of revenue for the foreseeable future. Finn’s cautious view fits that setup. The company has a valuable platform, but the price still depends on future success that is not proven yet.
The next year comes down to proof. Investors need to see better CASGEVY patient starts, a continued drop in collaboration expense, and cleaner data from programs such as zugo-cel, in vivo liver editing, and the siRNA work with Sirius. If those do not arrive, the stock remains mostly a pipeline bet with a costly first product.
Paid through partners, exposed to launch costs
CRISPR makes money mainly through collaborations. These can include upfront fees, milestones, royalties, and shared economics from products developed with partners. Its lead commercial product is CASGEVY, where Vertex leads research, development, manufacturing, and commercialization.
For CASGEVY, net profits and net losses are split 40 percent to CRISPR and 60 percent to Vertex. That sounds attractive once the product scales, but it cuts both ways. When launch and manufacturing costs run ahead of revenue, CRISPR must absorb its share.
The cost-deferral safety valve changed at the start of 2025. CRISPR no longer has the option to defer those CASGEVY costs, which is why the net collaboration expense became central to the thesis. Q2 2026 looked better than feared as revenues began offsetting costs, but one quarter does not prove breakeven.
The company also expanded beyond CRISPR editing through Sirius Therapeutics. The Sirius deal shares costs and profits equally for collaboration products and includes siRNA drugs. This adds another shot on goal, but also adds spending before any commercial return.
Five shots on gene-based medicine
CASGEVY for blood disorders
CASGEVY is the lead asset and the only approved product in the portfolio. It treats eligible patients with severe sickle cell disease or transfusion-dependent beta-thalassemia and is sold with Vertex.
Zugo-cel and CAR T programs
Zugo-cel is a next-generation allogeneic CAR T cell therapy. CRISPR is testing it in B-cell cancers and several autoimmune diseases, where data could change the story quickly.
In vivo liver editing
The in vivo programs aim to edit genes inside the body using lipid nanoparticles. CTX310 targets ANGPTL3, while other liver programs target cardiovascular and rare disease biology.
Regenerative medicine and diabetes
CRISPR is developing stem cell-derived, gene-edited cell therapies for type 1 diabetes. The work is early, but success would open a large market beyond rare blood diseases.
siRNA therapies with Sirius
The Sirius collaboration adds siRNA drugs to the pipeline. The deal gives CRISPR a non-editing platform, but it also brings shared development costs.
One business, two reported revenue lines
CRISPR manages the company as one operating segment. The mix shown here uses historically reported revenue lines, not separate business divisions.
What could break the thesis
CASGEVY uptake stalls
High impact · Medium oddsCRISPR depends on Vertex to manufacture and commercialize CASGEVY. If patient starts, treatment-center capacity, or reimbursement deals come in slowly, CRISPR’s 40 percent share may stay loss-making for longer. The product can still be medically important while being financially slow to scale.
Collaboration expense stays high
High impact · Medium oddsQ2 2026 collaboration expense improved to $40.3 million, but that is still a large quarterly cost. The key question is whether CASGEVY revenue keeps rising fast enough to offset launch and manufacturing spending. A reversal would push out the profit timeline again.
Pipeline trials disappoint
High impact · High oddsMost of CRISPR’s value still depends on clinical-stage or earlier programs. Gene editing, CAR T, diabetes cell therapy, in vivo editing, and siRNA all carry high failure risk. Bad safety signals or weak efficacy could remove major future growth paths.
Convertible debt dilutes shareholders
Medium impact · Medium oddsCRISPR raised about $585 million in net proceeds through $600 million of convertible senior notes due 2031. That strengthens the cash runway now, but it also adds debt and possible future share dilution if the notes convert. This matters because the company is still losing money.
IP risk is lower, not gone
Medium impact · Medium oddsThe ToolGen lawsuit against CRISPR tied to CASGEVY was dismissed in April 2026 without prejudice. Still, CRISPR operates in a crowded patent field where challenges can return in different forms. IP disputes can be costly even when the company wins.
In one breath
Is CRISPR Therapeutics profitable now that CASGEVY is approved?
No. The company is still reporting net losses. CASGEVY is approved, but launch and manufacturing costs still exceed CRISPR’s share of revenue.
Why does Vertex matter so much to CRISPR Therapeutics?
Vertex controls major parts of the CASGEVY program, including manufacturing and commercialization. CRISPR gets 40 percent of net profits or losses, so its results depend heavily on Vertex’s launch execution.
What is the main number to watch for CRSP?
Watch collaboration expense, net. It was $40.3 million in Q2 2026, down from $45.2 million in Q2 2025. It shows whether CASGEVY is moving closer to profitability for CRISPR.
What changed after the ToolGen lawsuit dismissal?
The dismissal removed a key near-term legal overhang around CASGEVY. It does not erase all intellectual property risk, because gene editing remains a complex patent area.
